86 related articles for article (PubMed ID: 37865978)
1. Response to the Comments from the Groupe Francophone de Cytogénétique Hématologique (GFCH) on the 5th edition of the World Health Organization classification of haematolymphoid tumors.
Siebert R; Schuh A; Ott G; Cree IA; Du MQ; Ferry J; Hochhaus A; Naresh KN; Solary E; Khoury JD
Leukemia; 2023 May; 37(5):1170-1172. PubMed ID: 36973349
[No Abstract] [Full Text] [Related]
2. How I diagnose myeloid neoplasms with germline predisposition.
Patel N; Calvo KR
Am J Clin Pathol; 2023 Oct; 160(4):352-364. PubMed ID: 37458302
[TBL] [Abstract][Full Text] [Related]
3. Germline Genetic Predisposition to Hematologic Malignancy.
Furutani E; Shimamura A
J Clin Oncol; 2017 Mar; 35(9):1018-1028. PubMed ID: 28297620
[TBL] [Abstract][Full Text] [Related]
4. Germline Predisposition in Hematologic Malignancies: Testing, Management, and Implications.
Godley LA; DiNardo CD; Bolton K
Am Soc Clin Oncol Educ Book; 2024 Jun; 44(3):e432218. PubMed ID: 38768412
[TBL] [Abstract][Full Text] [Related]
5. The landscape of cytogenetic and molecular genetic methods in diagnostics for hematologic neoplasia.
Behrens YL; Pietzsch S; Antić Ž; Zhang Y; Bergmann AK
Best Pract Res Clin Haematol; 2024 Mar; 37(1):101539. PubMed ID: 38490767
[TBL] [Abstract][Full Text] [Related]
6. The t(X;20)(q13;q13) translocation is a good prognostic factor in myeloid neoplasms: A report of 25 cases from the Groupe Francophone de Cytogénétique Hématologique.
Nguyen-Khac F; Muller M; Chapiro E; Abermil N; Collonge-Rame MA; Daudignon A; Gaillard B; Guzun D; Ittel A; Lefebvre C; Lesesve JF; Mozziconacci MJ; Penther D; Quessada J; Settegrana C; Smagghe L; Terre C; Veronese L; Hirsch P; Troadec MB
Am J Hematol; 2024 Apr; ():. PubMed ID: 38613825
[No Abstract] [Full Text] [Related]
7. Genomic testing for germline predisposition to hematologic malignancies.
Hwang SM
Blood Res; 2024 Mar; 59(1):12. PubMed ID: 38485837
[TBL] [Abstract][Full Text] [Related]
8. Introduction to a review series on germ line predisposition to hematologic malignancies: time to consider germ line testing.
Cazzola M
Blood; 2023 Mar; 141(13):1509-1512. PubMed ID: 36787501
[No Abstract] [Full Text] [Related]
9. Genetic predispositions to childhood leukemia.
Stieglitz E; Loh ML
Ther Adv Hematol; 2013 Aug; 4(4):270-90. PubMed ID: 23926459
[TBL] [Abstract][Full Text] [Related]
10. Rare Hematologic Malignancies and Pre-Leukemic Entities in Children and Adolescents Young Adults.
Brown A; Batra S
Cancers (Basel); 2024 Feb; 16(5):. PubMed ID: 38473358
[TBL] [Abstract][Full Text] [Related]
11. Universal germline genetic testing in patients with hematologic malignancies using DNA isolated from nail clippings.
Ceyhan-Birsoy O; Fiala E; Rana S; Sheehan M; Kennedy J; Yelskaya Z; Rai V; Li Y; Yang C; Wong D; Rijo I; Casanova J; Somar J; Mehta N; Park H; Ostafi S; Arora K; Padunan A; Ewalt MD; Aypar U; Terraf P; Misyura M; Haque S; Behr GG; Haque T; Sulis M; Geyer MB; Forlenza C; Thompson MC; Carlo M; Latham A; Liu Y; Zehir A; Brannon R; Berger M; Diaz LA; Dogan A; Ladanyi M; Petrova-Drus K; Nafa K; Offit K; Arcila M; Stadler ZK; Walsh MF; Mandelker D
Haematologica; 2024 Apr; ():. PubMed ID: 38572560
[TBL] [Abstract][Full Text] [Related]
12. The complex karyotype in hematological malignancies: a comprehensive overview by the Francophone Group of Hematological Cytogenetics (GFCH).
Nguyen-Khac F; Bidet A; Daudignon A; Lafage-Pochitaloff M; Ameye G; Bilhou-Nabéra C; Chapiro E; Collonge-Rame MA; Cuccuini W; Douet-Guilbert N; Eclache V; Luquet I; Michaux L; Nadal N; Penther D; Quilichini B; Terre C; Lefebvre C; Troadec MB; Véronèse L
Leukemia; 2022 Jun; 36(6):1451-1466. PubMed ID: 35430613
[TBL] [Abstract][Full Text] [Related]
13. Cytogenetics in the management of "chronic myeloid leukemia": an update by the Groupe francophone de cytogénétique hématologique (GFCH).
Roche-Lestienne C; Boudry-Labis E; Mozziconacci MJ
Ann Biol Clin (Paris); 2016 Oct; 74(5):511-515. PubMed ID: 27477825
[TBL] [Abstract][Full Text] [Related]
14. Cytogenetics in the management of B-cell acute lymphoblastic leukemia: Guidelines from the Groupe Francophone de Cytogénétique Hématologique (GFCH).
Tueur G; Quessada J; De Bie J; Cuccuini W; Toujani S; Lefebvre C; Luquet I; Michaux L; Lafage-Pochitaloff M
Curr Res Transl Med; 2023; 71(4):103434. PubMed ID: 38064905
[TBL] [Abstract][Full Text] [Related]
15. Cytogenetics in the management of acute myeloid leukemia and histiocytic/dendritic cell neoplasms: Guidelines from the Groupe Francophone de Cytogénétique Hématologique (GFCH).
Bidet A; Quessada J; Cuccuini W; Decamp M; Lafage-Pochitaloff M; Luquet I; Lefebvre C; Tueur G;
Curr Res Transl Med; 2023; 71(4):103421. PubMed ID: 38016419
[TBL] [Abstract][Full Text] [Related]
16. Cytogenetics in the management of hematologic neoplasms with germline predisposition: guidelines from the Groupe Francophone de Cytogénétique Hématologique (GFCH).
Gachard N; Lafage-Pochitaloff M; Quessada J; Auger N; Collonge-Rame MA
Curr Res Transl Med; 2023; 71(4):103416. PubMed ID: 37865978
[TBL] [Abstract][Full Text] [Related]
17. Cytogenetics in the management of hematologic malignancies: an update by the Groupe francophone de cytogénétique hématologique (GFCH).
Nguyen-Khac F; Daudignon A; Eclache V; Lafage-Pochitaloff M; Lefebvre C; Luquet I; Penther D
Ann Biol Clin (Paris); 2016 Oct; 74(5):509-510. PubMed ID: 27465598
[TBL] [Abstract][Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
